Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Trial Profile

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ripretinib (Primary) ; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms Intrigue
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 13 Aug 2019 According to an Deciphera Pharmaceuticals Media release, the company announced the commencement of a registered underwritten public offering of $200.0 million in shares of its common stock and intends to use these net proceeds for this trial.
    • 02 Aug 2019 According to a Deciphera Pharmaceuticals media release, the company continues to activate sites and and enroll patients. As of July 26, 2019, 45 sites have been activated.
    • 11 Jun 2019 According to a Deciphera Pharmaceuticals media release, the company intends to expand the trial and is currently assessing the addition of clinical trial sites in China.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top